Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 78
Selected: 0
NCT IDTitle
NCT03674814Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
NCT03335956CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
NCT02922257Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
NCT04373265Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
NCT03776812Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT05712265Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
NCT07240116Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
NCT06108219A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT03379363Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
NCT00796783A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
NCT03540836A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
NCT00698022A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
NCT04672512Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants
NCT05117489A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
NCT05347979Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
NCT05553470Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
NCT04308590A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
NCT04249323Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
NCT00455442A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
NCT06094712A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
NCT03508635CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
NCT03437941Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
NCT02014337Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
NCT05257408Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05772169Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
NCT02762981Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
NCT03697109A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
NCT01371565Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
NCT03067376A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
NCT06928779Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
NCT00130676A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
NCT00569582A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT03315338First-in-human Study in Healthy Subjects
NCT00752843A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
NCT00128479A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
NCT04672499Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants
NCT01925092Mifepristone in Children With Refractory Cushing's Disease
NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLD
NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT03258372Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
NCT04795479T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
NCT07259317Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT06094725A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
NCT02804750Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
NCT04588688Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency
NCT03604198Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03259542Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
NCT03512548Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
NCT05320146A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
NCT03818256A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications